Eleven to price initial public sale of stock between $13.00 and $15.00

Deal finances clinical trials and programs, general corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 23 - Eleven Biotherapeutics, Inc. will sell 4.3 million common shares in its initial public offering with a greenshoe of 645,000 additional shares, according to an S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced Dec. 30.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Citigroup Global Markets Inc., Cowen and Co., LLC and Leerink Partners LLC are the joint bookrunners.

Proceeds will be used for clinical programs, clinical trials, working capital and other general corporate purposes.

The biopharmaceutical company is based in Cambridge, Mass. It expects its shares will trade on the Nasdaq under the symbol "EBIO."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.